Abstract 443P
Background
Many patients with advanced cancer have difficulty eating and need nutritional support. This preliminary study examined the effects of individual nutritional counselling sessions on quality of life (QOL), nutritional status and eating-related distress (ERD) among patients with advanced cancer undergoing chemotherapy.
Methods
A survey was conducted in the outpatient chemotherapy center at a university hospital in Tokyo, Japan. Patients were offered individual nutritional counselling by a dietitian specializing in cancer. For the participants who completed at least two counselling sessions, we evaluated changes in their QOL (EORTC-QLQ C30), symptoms and nutritional status (PG-SGA SF) and ERD. Data were analyzed using the Wilcoxon signed rank test to compare mean differences. The ethics committee approved the study (Ethical Review No. M2015-578).
Results
Of 42 patients who applied for nutritional counselling, 8 underwent two sessions. The mean age was 70.6 ± 5.9 years and females accounted for 25.0%. Primary diseases were gastrointestinal cancer (n = 6) and lung cancer (n = 2). “Although family members and friends recommend foods to me, I am just confused” on the ERD and “fatigue” on the EORTC-QLQ C30 significantly improved (p < 0.05, respectively). There were no significant differences in the other items of the EORTC-QLQ C30 or symptoms and nutritional status on the PG-SGA SF. In total, 34 patients did not receive nutritional counselling twice because of death, changing hospitals, disease progression, or lack of coordination among researchers.
Conclusions
Our study suggests that individual nutritional counselling is slightly beneficial for patients with advanced cancer receiving chemotherapy. Further research is needed to demonstrate the effectiveness of this intervention in the future.
Clinical trial identification
UMIN registration No. UMIN000021540; was carried out prior to the start of the study.
Editorial acknowledgement
Legal entity responsible for the study
Tokyo Medical and Dental University.
Funding
Sasakawa Memorial Health Foundation.
Disclosure
S. Koshimoto: Research grant / Funding (institution): Sasakawa Memorial Health Foundation. All other authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract